沉默免疫负调控基因技术修饰的树突状细胞治疗原发性肝癌后T淋巴亚群分析  

Study on the cell therapy of inhibition of antigen-presentation attenuators to T-lymphocyte subsets of hepatocellular carcinoma patients

作　　者：徐献毅 任锋 陈德喜 李宁 谢棒祥 朴正福 

机构地区：[1]南京医科大学免疫学系,江苏南京211166 [2]首都医科大学附属北京佑安医院北京市肝病研究所

出　　处：《胃肠病学和肝病学杂志》2017年第11期1218-1221,共4页Chinese Journal of Gastroenterology and Hepatology

基　　金：北京市科委肝病研究基金(BJIH-01509)

摘　　要：目的探究使用沉默免疫负调控基因(iAPA)细胞疗法对原发性肝癌术后患者T淋巴细胞亚群的变化。方法选取南京医科大学附属医院12例原发性肝癌手术切除后患者,男7例,女5例,年龄37~73岁。术前用血细胞分离机采集外周血单个核细胞悬液60 ml,贴壁分离培养树突状细胞(DC),iAPA因子(含抑制SOCS1的siRNA等)转染DC。第7天将成熟的DC回输至患者体内。患者治疗两个疗程后,采用流式细胞术检测治疗前后外周血T淋巴细胞亚群。结果患者一般情况普遍得到明显改善。外周血T淋巴细胞亚群检测结果表明:CD3^+T淋巴细胞高于治疗前,CD3^+CD4^+T+CD3^+CD8^+T淋巴细胞比例之和高于治疗前,差异均有统计学意义(P<0.05)。结论 iAPA-DC疗法可以改善原发性肝癌免疫抑制状态,提高T淋巴细胞抗肿瘤效应,是有效的生物细胞技术之一。Objective To investigate the cell therapy of inhibition of antigen-presentation attenuators （iAPA） to T-lymphocyte subsets of hepatocellular carcinoma patients. Methods In this study, 12 patients with hepatocellular car- cinoma were selected in the Nanjing Medical University Affiliated Hospital. The patients were treated with iAPA cell therapy twice. The lymphocyte subsets in peripheral blood of patients were examined by flow cytometry. Results The general condition of patients were improved obsiously. The results showed that after iAPA cell therapy, the percentages of CD3 ~ T, and the sum of CD3 ＋ CD4 ＋ T and CD3 ＋ CD8 ＋ T were increased significantly than before the treatment, respectively （P 〈 0.05）. Conclusion iAPA cell therapy improve can immunosuppressive status and T-lymphocytes response in liver cancer patients, iAPA cell therapy is one of the effective biological technology.

关 键 词：免疫负调控基因 树突状细胞 原发性肝癌 T淋巴细胞亚群 

分 类 号：R735.7[医药卫生—肿瘤]